The FDA's CSA guidance formally replaces legacy validation models with a risk-based approach tied to intended use and patient safety impact. This paper covers the key framework elements, practical implementation considerations, and areas where additional FDA guidance is still needed.
Key topics include: risk classification at the feature level, flexible testing strategies, leveraging supplier evidence, 21 CFR Part 11 applicability, and the path forward for AI/ML systems.
You can read this document on this page or download it HERE
